BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 18, 2026
See today's BioWorld
Home
» Transition Could Get $130M in Diabetes Deal With Lilly
To read the full story,
subscribe
or
sign in
.
Transition Could Get $130M in Diabetes Deal With Lilly
March 17, 2008
By
Catherine Hollingsworth
Transition Therapeutics Inc. could receive up to $137 million in a deal with drug giant Eli Lilly and Co., which will acquire rights to Transition's gastrin-based therapies for diabetes. (BioWorld Today)
BioWorld
